Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and now, more ...

Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 ...

San Francisco and its hotel industry are partnering to beef up security around this week's 43rd annual J.P. Morgan Healthcare ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Browse in-depth TOC on " Global Biotechnology industry Outlook " 10 - Tables 20 - Figures 70 - Pages . The Global Biotech ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

On the first day of the J.P. Morgan Healthcare Conference, drug executives talked M&A, but also sized up the prospects of ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...